154 related articles for article (PubMed ID: 23603978)
1. Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.
Li QY; Xu MK; Liu G; Christoffersen CT; Wang MW
Acta Pharmacol Sin; 2013 Aug; 34(8):1116-20. PubMed ID: 23603978
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
Zagorska A; Partyka A; Bucki A; Gawalskax A; Czopek A; Pawlowski M
Curr Med Chem; 2018; 25(29):3455-3481. PubMed ID: 29521210
[TBL] [Abstract][Full Text] [Related]
4. New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).
Ribeiro CJA; Kankanala J; Shi K; Kurahashi K; Kiselev E; Ravji A; Pommier Y; Aihara H; Wang Z
Eur J Pharm Sci; 2018 Jun; 118():67-79. PubMed ID: 29574079
[TBL] [Abstract][Full Text] [Related]
5. Development of a High-Throughput Assay to Identify Inhibitors of ENPP1.
Kumar M; Lowery RG
SLAS Discov; 2021 Jun; 26(5):740-746. PubMed ID: 33402044
[TBL] [Abstract][Full Text] [Related]
6. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.
Huang YY; Yu YF; Zhang C; Chen Y; Zhou Q; Li Z; Zhou S; Li Z; Guo L; Wu D; Wu Y; Luo HB
J Med Chem; 2019 Apr; 62(7):3707-3721. PubMed ID: 30888810
[TBL] [Abstract][Full Text] [Related]
7. Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.
Ceyhan O; Birsoy K; Hoffman CS
Chem Biol; 2012 Jan; 19(1):155-63. PubMed ID: 22284362
[TBL] [Abstract][Full Text] [Related]
8. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay.
Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW
Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099
[TBL] [Abstract][Full Text] [Related]
9. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.
Yu YF; Zhang C; Huang YY; Zhang S; Zhou Q; Li X; Lai Z; Li Z; Gao Y; Wu Y; Guo L; Wu D; Luo HB
ACS Chem Neurosci; 2020 Apr; 11(7):1058-1071. PubMed ID: 32105440
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.
Weidlich IE; Dexheimer T; Marchand C; Antony S; Pommier Y; Nicklaus MC
Bioorg Med Chem; 2010 Jan; 18(1):182-9. PubMed ID: 19963390
[TBL] [Abstract][Full Text] [Related]
12. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.
Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS
Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534
[TBL] [Abstract][Full Text] [Related]
13. Development of a Scintillation Proximity Assay (SPA) Based, High Throughput Screening Feasible Method for the Identification of PDE12 Activity Modulators.
Mang S; Bucher H; Nickolaus P
Curr Drug Discov Technol; 2016; 13(3):144-151. PubMed ID: 27339127
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Zagórska A
Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
[No Abstract] [Full Text] [Related]
16. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
Yang SW; Smotryski J; McElroy WT; Tan Z; Ho G; Tulshian D; Greenlee WJ; Guzzi M; Zhang X; Mullins D; Xiao L; Hruza A; Chan TM; Rindgen D; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Jan; 22(1):235-9. PubMed ID: 22142545
[TBL] [Abstract][Full Text] [Related]
17. Papaverine-sensitive phosphodiesterase activity is measured in bovine spermatozoa.
Bergeron A; Hébert A; Guillemette C; Laroche A; Poulin MP; Aragon JP; Leclerc P; Sullivan R; Blondin P; Vigneault C; Richard FJ
Andrology; 2017 Jan; 5(1):169-179. PubMed ID: 27860455
[TBL] [Abstract][Full Text] [Related]
18. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
Lee YY; Park JS; Leem YH; Park JE; Kim DY; Choi YH; Park EM; Kang JL; Kim HS
J Neuroinflammation; 2019 Dec; 16(1):246. PubMed ID: 31791357
[TBL] [Abstract][Full Text] [Related]
19. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E
Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401
[TBL] [Abstract][Full Text] [Related]
20. Recombinant expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 4 (NPP4) and development of a luminescence-based assay to identify inhibitors.
Lopez V; Lee SY; Stephan H; Müller CE
Anal Biochem; 2020 Aug; 603():113774. PubMed ID: 32445636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
